New Danish allergy research company established  

2005.03.18
NOVI Innovation, pharmaceutical company ALK-Abelló and Denmark's National Hospital have jointly established a new allergy research company, T-Shift

NOVI Innovation, pharmaceutical company ALK-Abelló and Denmark's National Hospital have jointly established a new allergy research company, T-Shift. It will conduct research into new innovative allergy treatments via a recently patented technology. ALK-Abelló and Denmark's National Hospital have contributed with patent rights to the technology, while NOVI Innovation has invested seed capital of DKK 1,5 mn (USD 270,000).

 

Lars K. Poulsen, research director of the Allergy Clinic of Denmark's National Hospital, who will head T-Shift, says the company has not yet finally decided which type of allergy it will focus on, but initially the technology is targeted towards IgE mediated allergy, which comprises asthma and hay fever. T-Shift aims to use the next 18 months to investigate whether the technology is sustainable for starting drug development. The news is reported by Ingeniøren (the Engineer) and financial daily newspaper Børsen.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×